About Trevena (NASDAQ:TRVN)
Trevena Inc. is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers. It is also developing TRV250, a G protein biased ligand targeting the o-receptor, as a compound with a non-narcotic mechanism for the treatment of migraine. TRV250 also may have utility in a range of other central nervous system (CNS) indications. It is focused on commencing a Phase I study of TRV250 in the United Kingdom. Its ABLE product platform is a collection of biological information, in vitro assays, know-how and expertise that it uses to identify unique G protein coupled receptors (GPCR)-targeted biased ligands with various pharmaceutical properties.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TRVN
CUSIPN/A
Phone610-354-8840
Debt
Debt-to-Equity Ratio0.45%
Current Ratio3.71%
Quick Ratio3.71%
Price-To-Earnings
Trailing P/E Ratio-1.42
Forward P/E Ratio-1.94
P/E GrowthN/A
Sales & Book Value
Annual Sales$3.75 million
Price / Sales30.89
Cash FlowN/A
Price / CashN/A
Book Value$0.56 per share
Price / Book3.09
Profitability
EPS (Most Recent Fiscal Year)($1.21)
Net Income$-71,860,000.00
Net MarginsN/A
Return on Equity-140.68%
Return on Assets-81.64%
Miscellaneous
Employees51
Outstanding Shares66,950,000
Trevena (NASDAQ:TRVN) Frequently Asked Questions
What is Trevena's stock symbol?
Trevena trades on the NASDAQ under the ticker symbol "TRVN."
How were Trevena's earnings last quarter?
Trevena Inc (NASDAQ:TRVN) posted its earnings results on Wednesday, March, 7th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, topping analysts' consensus estimates of ($0.26) by $0.02. View Trevena's Earnings History.
When is Trevena's next earnings date?
What price target have analysts set for TRVN?
6 brokers have issued 1-year price objectives for Trevena's shares. Their forecasts range from $2.50 to $10.00. On average, they anticipate Trevena's stock price to reach $6.75 in the next twelve months. View Analyst Ratings for Trevena.
What are Wall Street analysts saying about Trevena stock?
Here are some recent quotes from research analysts about Trevena stock:
- 1. According to Zacks Investment Research, "Trevena, Inc. is a biopharmaceutical company. It focuses on discovering and developing therapeutics for G protein coupled receptors. The Company's product pipeline includes TRV027, TRV130, TRV734 and Delta opioid biased ligand which are in different clinical phases. Trevena, Inc. is based in King of Prussia, Pennsylvania. " (1/20/2018)
- 2. Needham & Company LLC analysts commented, "Trevena announced 1Q17 financial results yesterday. Olinvo NDA submission in pain still on track for 4Q17. Phase 3 open-label ATHENA safety trial has reached 600pt enrollment. Company therefore likely to reach target 1100 pt exposures per FDA recommendation (~480pts treated in APOLLO trials) in near future. As a reminder, Olinvo Phase 3 APOLLO trials did not establish consistent statistically significant differentiation from morphine on secondary GI and respiratory endpoints. We believe observed trend was clinically meaningful, but have updated our models to reflect modest market penetration given likely challenges in communicating differentiation." (5/5/2017)
Who are some of Trevena's key competitors?
Some companies that are related to Trevena include Sinovac Biotech (SVA), Innate Pharma (IPHYF), Depomed (DEPO), ProMetic Life Sciences (PFSCF), MediciNova (MNOV), Concert Pharmaceuticals (CNCE), Prothena (PRTA), Synergy Pharmaceuticals (SGYP), Sienna Biopharmaceuticals (SNNA), Cara Therapeutics (CARA), Syros Pharmaceuticals (SYRS), Cytokinetics (CYTK), Kala Pharmaceuticals (KALA), GTX (GTXI) and Albireo (ALBO).
Who are Trevena's key executives?
Trevena's management team includes the folowing people:
- Leon O. Moulder Jr., Independent Chairman of the Board (Age 59)
- Maxine Gowen Ph.D., President, Chief Executive Officer, Director (Age 59)
- Roberto E. Cuca, Chief Financial Officer, Senior Vice President (Age 49)
- Carrie L. Bourdow, Chief Operating Officer, Executive Vice President (Age 55)
- John M. Limongelli Esq., Chief Administrative Officer, Senior Vice President, General Counsel, Secretary (Age 47)
- Yacoub Habib Ph.D., Senior Vice President - Business Development and Corporate Planning (Age 49)
- David Soergel M.D., Senior Vice President - Clinical Development , Chief Medical Officer (Age 49)
- Michael R. Dougherty, Independent Director (Age 59)
- Adam M. Koppel M.D. Ph.D., Independent Director (Age 47)
- Julie H. McHugh, Independent Director (Age 52)
Has Trevena been receiving favorable news coverage?
Media stories about TRVN stock have been trending somewhat negative recently, according to Accern Sentiment Analysis. The research group identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Trevena earned a coverage optimism score of -0.10 on Accern's scale. They also gave news articles about the biopharmaceutical company an impact score of 47.60 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term.
How do I buy shares of Trevena?
Shares of TRVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Trevena's stock price today?
One share of TRVN stock can currently be purchased for approximately $1.73.
How big of a company is Trevena?
Trevena has a market capitalization of $113.15 million and generates $3.75 million in revenue each year. The biopharmaceutical company earns $-71,860,000.00 in net income (profit) each year or ($1.21) on an earnings per share basis. Trevena employs 51 workers across the globe.
How can I contact Trevena?
Trevena's mailing address is 955 Chesterbrook Boulevard Suite 200, Chesterbrook PA, 19087. The biopharmaceutical company can be reached via phone at 610-354-8840 or via email at [email protected]
MarketBeat Community Rating for Trevena (TRVN)
MarketBeat's community ratings are surveys of what our community members think about Trevena and other stocks. Vote "Outperform" if you believe TRVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRVN will underperform the S&P 500 over the long term. You may vote once every thirty days.
Trevena (NASDAQ:TRVN) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
6 Wall Street analysts have issued ratings and price targets for Trevena in the last 12 months. Their average twelve-month price target is $6.75, suggesting that the stock has a possible upside of 290.17%. The high price target for TRVN is $10.00 and the low price target for TRVN is $2.50. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.83 | 2.86 | 2.90 | 2.91 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $6.75 | $7.7857 | $8.65 | $9.8636 |
| Price Target Upside: | 290.17% upside | 337.40% upside | 385.96% upside | 350.39% upside |
Trevena (NASDAQ:TRVN) Consensus Price Target History
Trevena (NASDAQ:TRVN) Analyst Ratings History
Show:
(Data available from 4/26/2016 forward)
Trevena (NASDAQ:TRVN) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Trevena (NASDAQ TRVN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 4.60%
Institutional Ownership Percentage: 49.03%
Trevena (NASDAQ TRVN) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/22/2018 | Yacoub Habib | SVP | Sell | 5,000 | $1.76 | $8,800.00 | |  |
| 11/9/2016 | Carrie L Bourdow | SVP | Buy | 4,000 | $4.34 | $17,360.00 | | |
| 11/7/2016 | Maxine Gowen | CEO | Buy | 12,500 | $4.10 | $51,250.00 | 16,500 | |
| 11/7/2016 | Yacoub Habib | SVP | Buy | 5,000 | $4.12 | $20,600.00 | 5,000 | |
| 5/27/2016 | Maxine Gowen | CEO | Buy | 22,084 | $7.12 | $157,238.08 | 279,025 | |
| 12/10/2015 | David Soergel | CMO | Sell | 27,217 | $10.55 | $287,139.35 | 1,750 | |
| 12/12/2014 | John M Limongelli | VP | Buy | 3,000 | $4.14 | $12,420.00 | | |
| 12/10/2014 | Enterprise Associates 12 New | Major Shareholder | Buy | 1,000,000 | $4.00 | $4,000,000.00 | | |
| 12/10/2014 | Maxine Gowen | CEO | Buy | 8,000 | $4.00 | $32,000.00 | | |
| 12/10/2014 | Michael R Dougherty | Director | Buy | 7,000 | $4.00 | $28,000.00 | | |
| 12/10/2014 | Michael W Lark | VP | Buy | 5,000 | $4.00 | $20,000.00 | | |
| 12/10/2014 | Roberto Cuca | CFO | Buy | 25,000 | $4.00 | $100,000.00 | | |
| 12/9/2014 | Leon O Moulder Jr | Director | Buy | 30,200 | $3.96 | $119,592.00 | | |
| 9/29/2014 | Rosamond Deegan | SVP | Sell | 44 | $7.00 | $308.00 | | |
| 2/5/2014 | Laboratories Holdings L Forest | Major Shareholder | Buy | 428,571 | $7.00 | $2,999,997.00 | | |
(Data available from 1/1/2013 forward)
Trevena (NASDAQ TRVN) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Biotech Stocks' Research Reports Released on TG Therapeutics, Trevena, Vanda Pharma, and Verastem
www.prnewswire.com - April 25 at 8:21 AM |
 | Trevena (TRVN) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - April 25 at 6:32 AM |
 | Police use dead man's finger in failed bid to unlock his cellphone
www.nbcnews.com - April 24 at 8:20 AM |
| Zacks: Analysts Expect Trevena Inc (TRVN) to Post -$0.19 EPS
www.americanbankingnews.com - April 16 at 5:15 AM |
| Trevena (TRVN) PT Set at $8.00 by Oppenheimer
www.americanbankingnews.com - April 13 at 10:53 AM |
 | BRIEF-Trevena Says Chief Financial Officer Roberto Cuca Will Resign, Effective May 3, 2018
www.reuters.com - April 13 at 8:20 AM |
 | Form 8-K TREVENA INC For: Apr 09
www.streetinsider.com - April 12 at 5:38 PM |
| Barclays Lowers Trevena (TRVN) to Equal Weight
www.americanbankingnews.com - April 7 at 10:53 AM |
| Zacks Investment Research Upgrades Trevena (TRVN) to "Buy"
www.americanbankingnews.com - April 6 at 3:01 PM |
| BRIEF-Trevena Announces Retirement Of Maxine Gowen, Ph.D., Effective October 1, And Planned Promotion Of Carrie ...
www.reuters.com - April 5 at 5:17 PM |
 | Trevena Announces Retirement of Maxine Gowen, Ph.D., Effective October 1, and Planned Promotion of Carrie L ...
globenewswire.com - April 5 at 5:17 PM |
| Trevena (TRVN) CEO Maxine Gowen to Retire; Announces Planned Promotion of Carrie L. Bourdow to President and ...
www.streetinsider.com - April 5 at 5:17 PM |
 | Trevena Announces Retirement of Maxine Gowen, Ph.D., Effective October 1, and Planned Promotion of Carrie L. Bourdow to President and Chief Executive Officer
finance.yahoo.com - April 5 at 5:17 PM |
| Founding CEO of Trevena biopharm firm to retire
finance.yahoo.com - April 5 at 5:17 PM |
| Trevena Inc (TRVN) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 4 at 3:25 AM |
| Zacks Investment Research Lowers Trevena (TRVN) to Hold
www.americanbankingnews.com - April 2 at 8:21 AM |
| Needham & Company LLC Trims Trevena (TRVN) Target Price to $7.00
www.americanbankingnews.com - April 1 at 10:29 AM |
| Edited Transcript of TRVN earnings conference call or presentation 7-Mar-18 1:00pm GMT
finance.yahoo.com - April 1 at 8:23 AM |
| -$0.19 Earnings Per Share Expected for Trevena Inc (TRVN) This Quarter
www.americanbankingnews.com - March 30 at 9:34 AM |
| Trevena's (TRVN) "Buy" Rating Reiterated at Oppenheimer
www.americanbankingnews.com - March 22 at 4:05 PM |
| Trevena to Present at the Needham & Company 17th Annual Healthcare Conference
finance.yahoo.com - March 20 at 5:16 PM |
 | Trevena (TRVN) Presents At 38th Annual Cowen And Company Healthcare Conference - Slideshow
seekingalpha.com - March 15 at 6:11 PM |
| Oppenheimer Analysts Lift Earnings Estimates for Trevena Inc (TRVN)
www.americanbankingnews.com - March 15 at 8:45 AM |
| Trevena to Present at the Oppenheimer & Company 28th Annual Healthcare Conference
finance.yahoo.com - March 14 at 7:06 PM |
| Oppenheimer Weighs in on Trevena Inc's FY2022 Earnings (TRVN)
www.americanbankingnews.com - March 14 at 4:24 PM |
| Trevena Inc (TRVN) Expected to Announce Earnings of -$0.20 Per Share
www.americanbankingnews.com - March 13 at 5:12 AM |
| Trevena (TRVN) Given a $5.00 Price Target at Oppenheimer
www.americanbankingnews.com - March 12 at 7:10 PM |
| Trevena Inc to Post FY2018 Earnings of ($0.85) Per Share, Jefferies Group Forecasts (TRVN)
www.americanbankingnews.com - March 12 at 4:22 AM |
| Trevena Inc (TRVN) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - March 10 at 4:14 AM |
| Trevena Inc (TRVN) Forecasted to Post Q1 2018 Earnings of ($0.21) Per Share
www.americanbankingnews.com - March 9 at 8:53 AM |
| HC Wainwright Boosts Trevena (TRVN) Price Target to $7.00
www.americanbankingnews.com - March 8 at 11:04 PM |
| Trevena (TRVN) Posts Earnings Results, Beats Estimates By $0.03 EPS
www.americanbankingnews.com - March 8 at 9:04 AM |
| Trevena, Inc. to Host Earnings Call
finance.yahoo.com - March 7 at 6:33 PM |
| Trevena Reports Full Year 2017 Earnings
finance.yahoo.com - March 7 at 6:33 PM |
| Trevena Inc (NASDAQ:TRVN): When Will It Breakeven?
finance.yahoo.com - March 7 at 6:33 PM |
| Trevena to Present at the Cowen and Company 38th Annual Healthcare Conference
finance.yahoo.com - March 7 at 6:33 PM |
| Trevena Reports Full Year 2017 Earnings - GlobeNewswire (press release)
globenewswire.com - March 7 at 8:19 AM |
| Head-To-Head Review: Trevena (TRVN) versus Edge Therapeutics (EDGE)
www.americanbankingnews.com - March 3 at 10:34 AM |
| Trevena Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
finance.yahoo.com - March 2 at 6:09 PM |
| Trevena to Host Conference Call on March 7th to Discuss Full Year 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - February 28 at 8:18 AM |
| Trevena to Host Conference Call on March 7th to Discuss Full Year 2017 Financial Results
finance.yahoo.com - February 28 at 8:18 AM |
| Trevena (TRVN) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - February 27 at 2:34 AM |
| -$0.26 Earnings Per Share Expected for Trevena Inc (TRVN) This Quarter
www.americanbankingnews.com - February 24 at 8:06 AM |
| Quotidian Technical Highlights on Selected Biotech Stocks -- Tesaro, Trevena, Vanda Pharma, and Verastem - PR Newswire (press release)
www.prnewswire.com - February 21 at 8:23 AM |
| Trevena Inc (TRVN) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - February 13 at 3:30 AM |
| Head to Head Comparison: Denali Therapeutics (DNLI) and Trevena (TRVN)
www.americanbankingnews.com - February 8 at 5:22 PM |
| Brokerages Expect Trevena Inc (TRVN) to Announce -$0.26 EPS
www.americanbankingnews.com - February 7 at 9:52 AM |
| Trevena (TRVN) Promotes Carrie Bourdow to Executive Vice President and COO - StreetInsider.com
www.streetinsider.com - February 3 at 9:31 AM |
| Trevena Promotes Carrie Bourdow to Executive Vice President and Chief Operating Officer
finance.yahoo.com - February 2 at 9:31 AM |
| Trevena (TRVN) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - January 20 at 8:22 PM |
Trevena (NASDAQ:TRVN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Trevena (NASDAQ:TRVN) Income Statement, Balance Sheet and Cash Flow Statement
Trevena (NASDAQ TRVN) Stock Chart for Thursday, April, 26, 2018
Loading chart…
